TriGemX Bio Raises $94M for Phase 3 Migraine Trials

TriGemX Bio has closed a $94M financing to carry elismetrep, an investigational oral TRPM8 channel blocker, through a Phase 3 program in acute migraine. The October 1 financing was co-led by The Column Group, TCGX and Viking Global Investors. The company did not disclose a series label, valuation, financing instrument or the identities of additional participating investors.

The transaction arrives with an institutional reset. Kallyope is relaunching as TriGemX Bio, Jeff Goater is becoming CEO, Aninda Katragadda is joining as CFO and Brett Lauring, MD, PhD, remains CMO. TCGX Managing Partner Cariad Chester is also joining the board.

Brand, leadership and capital are now organized around one late-stage question: can a mechanism linked to migraine genetics produce reliable relief in pivotal trials? Elismetrep has supportive Phase 2b evidence, but the primary eDiary analysis of two-hour pain freedom did not reach conventional statistical significance. The Phase 3 program has to resolve that evidence at a scale built for regulatory review.

What TriGemX Bio Funded

The $94M will support the clinical development of elismetrep, also known as K-304, for the acute treatment of migraine. The company says results from its first pivotal study are expected in mid-2027. A second pivotal study and a long-term safety study complete the publicly registered Phase 3 program.

The round also marks a change in operating identity. Kallyope launched in 2015 around a broad gut-brain biology platform founded by neuroscientists Charles Zuker, Tom Maniatis and Richard Axel. It previously announced $479M across Series A through Series D financings. The TriGemX name, a reference to the trigeminal ganglion, gives the company a public identity tied directly to the neural structure and migraine program now carrying its future.

That history matters because this financing is more than another balance-sheet extension. TriGemX Bio is concentrating a decade of science, investor support and company building around one pivotal asset. The undisclosed financing structure prevents a clean cumulative-equity calculation, and the company did not provide a new valuation.

The Evidence Behind Elismetrep

Elismetrep blocks TRPM8, a cation channel expressed in trigeminal and other sensory neurons. Large migraine genetic studies have identified risk variants near the TRPM8 locus, giving the target a human-genetics rationale. TriGemX Bio argues that the mechanism is distinct from existing acute-migraine drug classes, including CGRP-targeted therapies.

The completed Phase 2b study, NCT06848075, randomized 431 participants and treated 398 qualifying migraine attacks. According to the company's 2026 American Academy of Neurology abstract, the 20 mg dose produced two-hour pain freedom in 17.6% of participants versus 9.1% for placebo in the primary eDiary analysis. The reported p value was 0.0650, above the conventional 0.05 threshold.

A prespecified supporting analysis that used recalled data when two-hour diary entries were missing showed pain freedom of 19.6% versus 9.1%, with nominal p=0.0344. Secondary measures also favored elismetrep: freedom from the most bothersome symptom was 38.3% versus 24.2%, while pain relief was 58.8% versus 42.4%, both with nominal p values below 0.05.

No serious adverse events were reported in the abstract. At 20 mg, adverse events were mild or moderate; the most common included oral paresthesia, feeling hot, paresthesia, hot flush and flushing. Those results support continued development, while the mixed statistical picture explains why the pivotal program carries so much weight.

A Three-Study Phase 3 Program

The first pivotal Phase 3 study, NCT07645924, is recruiting with estimated enrollment of 1,800 and primary completion listed for February 2027. A long-term safety study, NCT07674654, is also recruiting with estimated enrollment of 1,000 and completion scheduled for 2028.

The second pivotal efficacy study, NCT07816367, is listed as not yet recruiting with estimated enrollment of 1,500. TriGemX Bio said that study would begin in October 2026. Elismetrep remains investigational and has not been approved by the FDA or another regulator.

The late-stage design puts the company's operating claims on a fixed calendar. TriGemX Bio has to reproduce clinically meaningful benefit, establish safety across broader exposure and show that the new liquid-filled soft-gel formulation performs consistently. The first readout may arrive in mid-2027, while the long-term safety record will continue developing beyond that point.

Leadership Moves Closer to the Asset

Jeff Goater's appointment brings investor and operating experience into the CEO role. Goater remains a Venture Partner at The Column Group and previously served as CEO of Surface Oncology and CFO of Voyager Therapeutics. He has been involved with Kallyope at the board level, so the transition places someone familiar with the company inside the execution seat as the pivotal program advances.

Aninda Katragadda joins as CFO after serving in the same role at Atavistik Bio and holding finance positions across Akouos, Surface Oncology, Foghorn Therapeutics, Voyager Therapeutics, The Medicines Company and Vertex. Brett Lauring continues to lead clinical development as CMO, including the Phase 2b program and the move into Phase 3.

The investor group reinforces that alignment. The Column Group has backed Kallyope since its launch, TCGX brings later-stage biotechnology capital and Viking Global adds another new lead investor. Cariad Chester's board appointment connects that financing directly to governance during the clinical phase that will determine the company's next options.

Why a New Migraine Mechanism Matters

Migraine affects more than one billion people worldwide, according to large global genetic and epidemiological studies, and the World Health Organization identifies it as a major source of neurological disability. Acute treatment already includes several drug classes, but individual response, tolerability and contraindications leave many patients cycling through options.

TRPM8 gives TriGemX Bio a differentiated biological entry point. The opportunity is meaningful because the target is connected to migraine genetics and sits in sensory pathways relevant to an attack. The risk is equally clear: mechanistic novelty does not guarantee a clinically persuasive result, and the Phase 2b record still needs pivotal confirmation.

TriGemX Bio has now given that work a new corporate name, a new leadership configuration and $94M of additional financing. The first Phase 3 readout will show whether the company has built an identity around a medicine that can carry it.